Bristol Vanlev Launch Resources Will Shift To Pravachol; NDA Withdrawn

Bristol plans to reallocate some of the money reserved for the launch of the antihypertensive Vanlev to help revive the cholesterol-lowering agent Pravachol.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet